Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Covidien Ltd.

Division of Medtronic PLC
www.covidien.com

Latest From Covidien Ltd.

Market Brief: Global Market For Endoscopic Surgeries Will Reach $17.7Bn In 2023

The global market for endoscopic and pelvic surgery procedures is expected to reach $17.7bn in 2023, a CAGR of 6.4%, driven by patients' demand for less invasive surgeries and physicians' preference for minimally invasive surgeries versus open surgeries. By 2023, the number of general and pelvic endoscopic procedures performed globally will reach about 29.7 million, representing a CAGR of 3.6%.

Innovation Market Intelligence

Device Settlements Contribute To DoJ's $2.5Bn Health-Care FCA Haul

The US Department of Justice collected $2.8bn in settlements and judgments involving violations of the False Claims Act in 2018, including $2.5bn in health-care cases. Key device industry recoveries included $33.2m from Alere, $12.5m from Angiodynamics, and $30m in two separate settlements from Covidien and its subsidiary ev3.

Medical Device Legal Issues

Medtronic Biz Pleads Guilty In Off-Label Marketing Case

A Medtronic subsidiary has agreed to plead guilty for off-label marketing activities that occurred prior to Medtronic's acquisition. Overall, the firm says it has settled three investigations with a total pay-out of $50.9m. US FDA is underscoring the case as an example of the agency pursuing companies that "put profit over safety."

Enforcement Compliance

Israel's Medtech Market Evolution: Seeking The Next Big Thing

Medtronic’s multi-billion-dollar acquisition of Mazor Robotics in 2018 marked a record-breaking milestone for Israel’s life sciences industry as the largest amount ever paid for an Israeli company in the medical sector, beating Mitsubishi Tanabe Pharma’s $1.1 billion acquisition of Neuroderm in 2017. In Vivo investigates how aMoon II, a new VC fund, aims to produce the industry’s next big giant.

Growth Deals
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register